US politics live: Prosecutor in Jeffrey Epstein's case, Maurene Comey, fired
Maurene Comey, the federal prosecutor who worked on the criminal cases against Jeffrey Epstein and Ghislaine Maxwell, has reportedly been fired.
Ms Comey, the daughter of former FBI director James Comey – who Donald Trump sacked during his first term, was reportedly given a letter informing her of the termination on Wednesday, three people with knowledge of the matter told The New York Times.
According to two of the people with knowledge of the matter, the letter given to Ms Comey said she was being fired under Article II of the US Constitution, which describes the powers granted to the President.
The news followed Mr Trump unleashing on some of his own supporters in a furious tirade, calling them 'weaklings' and accusing them of falling for a 'bulls**t … scam' as the fallout from the Epstein files continues.
Mr Trump is facing the most serious split of his political career from his famously loyal right-wing base over suspicions his administration is covering up lurid details of the convicted child sex offender's crimes in order to protect rich and powerful figures they say are implicated.
Read on for the latest updates
Originally published as US politics live: Prosecutor in Jeffrey Epstein's case, Maurene Comey, fired
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
11 minutes ago
- West Australian
Trade stand-off continues as US drug tariffs loom
Australia's pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US threats to triple the price of foreign medicines. In a continuation of his erratic approach to trade policy, President Donald Trump says taxes on drug imports could be announced as soon as the end of the month, with eventual tariff rates of up to 200 per cent. "We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff," Mr Trump said. Australia's Pharmaceutical Benefits Scheme, under which the government negotiates medicine prices with manufacturers before subsidising them for patients, is reportedly in the crosshairs of US pharmaceutical companies lobbying the White House. The Albanese government has flatly refused any negotiation on the PBS. "Obviously, they are being lobbied, as other US Presidents have been for many years by the US big pharma industry, which wants not just Australia's scheme but other schemes like it around the world ... they want that freed up," federal health minister Mark Butler said on Wednesday. "They want to see their profits increased. That's been the case for decades and decades." The PBS is crucial to ensure equitable and affordable access to medicines, according to Royal Australian College of GPs president Michael Wright. "We should be proud of the prime minister and treasurer's steadfast support for maintaining the PBS, regardless of external pressure." But complaints about such pricing schemes are common across the industry and include Australian medicine manufacturers, says Melbourne University research fellow Joe Carrello. "They argue the increasing costs it takes to investigate and run trials and bring a new drug to market aren't keeping up with what the return is, given what the government is willing to pay," Dr Carrello told AAP. Dr Carrello, who helps evaluate medicines proposed for the PBS after their approval by the Therapeutic Goods Administration, said there could be consequences to a relatively small market like Australia negotiating such lean prices. "The fear is some US companies may decide against launching new drugs in Australia because comparatively, they're not going to get a good price," he said. In the US, where a relatively free-market approach has been favoured, drug prices are almost three times higher than in 33 comparable income countries, according to RAND research. Australians have an average life expectancy of 83.2 years, compared to 77.4 years in the US, World Bank data shows. "Without the PBS, we'd see people losing access to affordable medications and an increased spend per person on average but it wouldn't be evenly distributed," Dr Carrello said. In a submission to a Productivity Commission inquiry, pharmaceutical giant Pfizer criticised the PBS's assessment process, claiming it under-accounted for drug and vaccine benefits over multiple budget cycles and missed broader social benefits. "Over the last decade, while the total PBS spend has increased, the proportion of the PBS that funds innovative medicines has seen minimal growth," Pfizer wrote in its submission. "This means, as a proportion of GDP, the government's expenditure on innovative medicines is going backwards." Federal treasurer Jim Chalmers has joined the health minister in ruling out any changes to the PBS in US trade negotiations. "This Albanese Labor government is about strengthening the PBS in the interests of our people, not weakening it in the interests of American multinationals," he recently said. As for Australian drug producers, the federal government was still weighing the impacts of the proposed tariffs on Australian exports, which were worth $2.2 billion in 2024. "(President Trump) indicated there was a long lead time, a long period where he'd be considering this possible step," Dr Chalmers said. That lead time was cut by a matter of months this week, in a sign the United States' push may be turning to a shove.
Perth Now
11 minutes ago
- Perth Now
Trade stand-off continues as US drug tariffs loom
Australia's pharmaceutical benefits scheme is not up for negotiation, says the federal government in the face of ramped-up US threats to triple the price of foreign medicines. In a continuation of his erratic approach to trade policy, President Donald Trump says taxes on drug imports could be announced as soon as the end of the month, with eventual tariff rates of up to 200 per cent. "We're going to start off with a low tariff and give the pharmaceutical companies a year or so to build, and then we're going to make it a very high tariff," Mr Trump said. Australia's Pharmaceutical Benefits Scheme, under which the government negotiates medicine prices with manufacturers before subsidising them for patients, is reportedly in the crosshairs of US pharmaceutical companies lobbying the White House. The Albanese government has flatly refused any negotiation on the PBS. "Obviously, they are being lobbied, as other US Presidents have been for many years by the US big pharma industry, which wants not just Australia's scheme but other schemes like it around the world ... they want that freed up," federal health minister Mark Butler said on Wednesday. "They want to see their profits increased. That's been the case for decades and decades." The PBS is crucial to ensure equitable and affordable access to medicines, according to Royal Australian College of GPs president Michael Wright. "We should be proud of the prime minister and treasurer's steadfast support for maintaining the PBS, regardless of external pressure." But complaints about such pricing schemes are common across the industry and include Australian medicine manufacturers, says Melbourne University research fellow Joe Carrello. "They argue the increasing costs it takes to investigate and run trials and bring a new drug to market aren't keeping up with what the return is, given what the government is willing to pay," Dr Carrello told AAP. Dr Carrello, who helps evaluate medicines proposed for the PBS after their approval by the Therapeutic Goods Administration, said there could be consequences to a relatively small market like Australia negotiating such lean prices. "The fear is some US companies may decide against launching new drugs in Australia because comparatively, they're not going to get a good price," he said. In the US, where a relatively free-market approach has been favoured, drug prices are almost three times higher than in 33 comparable income countries, according to RAND research. Australians have an average life expectancy of 83.2 years, compared to 77.4 years in the US, World Bank data shows. "Without the PBS, we'd see people losing access to affordable medications and an increased spend per person on average but it wouldn't be evenly distributed," Dr Carrello said. In a submission to a Productivity Commission inquiry, pharmaceutical giant Pfizer criticised the PBS's assessment process, claiming it under-accounted for drug and vaccine benefits over multiple budget cycles and missed broader social benefits. "Over the last decade, while the total PBS spend has increased, the proportion of the PBS that funds innovative medicines has seen minimal growth," Pfizer wrote in its submission. "This means, as a proportion of GDP, the government's expenditure on innovative medicines is going backwards." Federal treasurer Jim Chalmers has joined the health minister in ruling out any changes to the PBS in US trade negotiations. "This Albanese Labor government is about strengthening the PBS in the interests of our people, not weakening it in the interests of American multinationals," he recently said. As for Australian drug producers, the federal government was still weighing the impacts of the proposed tariffs on Australian exports, which were worth $2.2 billion in 2024. "(President Trump) indicated there was a long lead time, a long period where he'd be considering this possible step," Dr Chalmers said. That lead time was cut by a matter of months this week, in a sign the United States' push may be turning to a shove.
Daily Telegraph
3 hours ago
- Daily Telegraph
Dozens injured after Hollywood car ramming
Don't miss out on the headlines from World. Followed categories will be added to My News. More than 30 people were hurt after a driver ploughed into a crowd standing outside a Los Angeles nightclub on Friday night, US time, according to officials. Seven of the victims were in a critical condition after the incident, which unfolded at 2am on Saturday when a Nissan Versa car flew into the crowd outside of The Vermont Hollywood club on Santa Monica Boulevard, in East Hollywood, the New York Post reports. Police patrol vehicles close Vermont Ave. after a vehicle rammed into a crowd gathered outside The Vermont nightclub in Los Angeles, early morning Saturday, July 19, 2025. (AP Photo/Damian Dovarganes) 'They were all standing in line going into a nightclub. There was a taco cart out there, so they were … getting some food, waiting to go in. And there's also a valet line out there,' Los Angeles Fire Department Captain Adam VanGerpen said. An area is roped off after a vehicle rammed into a crowd of people waiting to enter a nightclub along a busy boulevard in Los Angeles early Saturday, July 19, 2025, injuring several people. (AP Photo/Damian Dovarganes) A vehicle sits on the sidewalk after ramming into a crowd of people waiting to enter a nightclub along a busy boulevard in Los Angeles early Saturday, July 19, 2025 injuring several people. (AP Photo/Damian Dovarganes) 'The valet podium was taken out, the taco truck was taken out, and then a large number of people were impacted by the vehicle.' The majority of the people in line for the concert at the nightclub, which was billed as 'So-Cal's Biggest Reggaeton & Hip-Hop Party,' were women, according to Capt VanGerpen. At least three victims were in critical condition. One of the patients had a gunshot wound, said paramedics, but the victim had yet to be identified and it was unclear if that victim was connected to the crash. The majority of the 31 patients were being treated and transported to area hospitals and trauma centres, Capt Van Gerpen said. People inside the club came out to help the victims in the minutes before emergency crews arrived on the scene, the captain said. This story was published in the New York Post and is reproduced with permission. Originally published as Dozens injured after Hollywood car ramming
